G-protein coupled receptor 40 agonists as novel therapeutics for type 2 diabetes

Archives of Pharmacal Research

Volumn 37, Issue 4, 2014, Pages 435-439

  Choi, Yun Jung ^a   Shin, Dongyun ^b   Lee, Ju Yeun ^a  

^a Hanyang University   (South Korea)

^b Gachon University College of Medicine   (South Korea)

Author keywords

Antidiabetics; GPR40 agonist; Type 2 diabetes mellitus

Indexed keywords

AMG 837; ANTIDIABETIC AGENT; FASIGLIFAM; G PROTEIN COUPLED RECEPTOR 40; GLIMEPIRIDE; GLUCOSE; INSULIN; UNCLASSIFIED DRUG; BENZOFURAN DERIVATIVE; BIPHENYL DERIVATIVE; FFAR1 PROTEIN, HUMAN; G PROTEIN COUPLED RECEPTOR; NEW DRUG; SULFONE; TAK-875;

ARTICLE; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); AGONISTS; DIABETES MELLITUS, TYPE 2; DRUG DEVELOPMENT; DRUG EFFECTS; SIGNAL TRANSDUCTION;

BENZOFURANS; BIPHENYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; DRUG DISCOVERY; DRUGS, INVESTIGATIONAL; HUMANS; HYPOGLYCEMIC AGENTS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; SULFONES;

EID: 84897554321     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-013-0283-3     Document Type: Article

References (28)

1. Araki, T.; M. Hirayama, S. Hiroi, and K. Kaku. 2012. GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes. Diabetes, Obesity & Metabolism 14: 271-278.
2. Bartoov-Shifman, R.; G. Ridner, K. Bahar, N. Rubins, and M.D. Walker. 2007. Regulation of the gene encoding GPR40, a fatty acid receptor expressed selectively in pancreatic beta cells. The Journal of Biological Chemistry 282(32): 23561-23571.
3. Briscoe, C.P.; A.J. Peat, S.C. McKeown, D.F. Corbett, A.S. Goetz, T.R. Littleton, D.C. McCoy, T.P. Kenakin, J.L. Andrews, C. Ammala, J.A. Fornwald, D.M. Ignar, and S. Jenkinson. 2006. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. British Journal of Pharmacology 148: 619-628.
4. Burant, C.F.; P. Viswanathan, J. Marcinak, C. Cao, M. Vakilynejad, B. Xie, and E. Leifke. 2012. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 379: 1403-1411.
5. Chao, E.C. 2012. Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes. Core Evidence 7: 21-28.
6. Gough, S.C.; A. Bhargava, R. Jain, H. Mersebach, S. Rasmussen, and R.M. Bergenstal. 2013. Low-volume insulin degludec 200 units/mL once daily improves glycemic control similar to insulin glargine with a low risk of hypoglycemia in insulin-naïve patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care. doi: 10.2337/dc12-2329.
7. Gravena, C.; P.C. Mathias, and S.J. Ashcroft. 2002. Acute effects of fatty acids on insulin secretion from rat and human islets of Langerhans. Journal of Endocrinology 173: 73-80.
8. Haber, E.P.; H.M. Ximenes, J. Procopio, C.R. Carvalho, R. Curi, and A.R. Carpinelli. 2003. Pleiotropic effects of fatty acids on pancreatic ß-cells. Journal of Cellular Physiology 194: 1-12.
9. Henquin, J.C. 2000. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 49: 1751-1760.
10. Itoh, Y.; Y. Kawamata, M. Harada, M. Kobayashi, R. Fujii, S. Fukusumi, K. Ogi, M. Hosoya, Y. Tanaka, H. Uejima, H. Tanaka, M. Maruyama, R. Satoh, S. Okubo, H. Kizawa, H. Komatsu, F. Matsumura, Y. Noguchi, T. Shinohara, S. Hinuma, Y. Fujisawa, and M. Fujino. 2003. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 13(422): 173-176.
11. Kim, S.; Y.M. Kim, and Y.S. Kwak. 2012. A novel therapeutic target, GPR43; where it stands in drug discovery. Archives of Pharmacal Research 35: 1505-1509.
12. Kim, S.H.; S.H. Lee, and H.J. Yim. 2013. Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry. Archives of Pharmacal Research 36: 1185-1188.
13. Luo, J.; G. Swaminath, S.P. Brown, J. Zhang, Q. Guo, M. Chen, K. Nguyen, T. Tran, L. Miao, P.J. Dransfield, M. Vimolratana, J.B. Houze, S. Wong, M. Toteva, B. Shan, F. Li, R. Zhuang, and D.C. Lin. 2012. A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents. PLoS One 7: e46300.
14. Morgan, N.G.; and S. Dhayal. 2009. G-protein coupled receptors mediating long chain fatty acid signaling in the pancreatic beta-cell. Biochemical Pharmacology 78: 1419-1427.
15. Nagasumi, K.; R. Esaki, K. Iwachidow, Y. Yasuhara, K. Ogi, H. Tanaka, M. Nakata, T. Yano, K. Shimakawa, S. Taketomi, K. Takeuchi, H. Odaka, and Y. Kaisho. 2009. Overexpression of GPR40 in pancreatic β-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes 58: 1067-1076.
16. Naik, H.; J. Lu, C. Cao, M. Pfister, M. Vakilynejad, and E. Leifke. 2013. Pharmacometric approaches to guide dose selection of the novel GPR40 agonist TAK-875 in subjects with Type 2 diabetes mellitus. Pharmacometrics & Systems Pharmacology 2: e22. doi: 10.1038/psp.2012.23.
17. Negoro, N.; S. Sasaki, S. Mikami, M. Ito, Y. Tsujihata, R. Ito, M. Suzuki, K. Takeuchi, N. Suzuki, J. Miyazaki, T. Santou, T. Odani, N. Kanzaki, M. Funami, A. Morohashi, M. Nonaka, S. Matsunaga, T. Yasuma, and Y. Momose. 2012. Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent. Journal of Medicinal Chemistry 55: 3960-3974.
18. Oh, D.Y.; and W.S. Lagakos. 2011. The role of G-protein-coupled receptors in mediating the effect of fatty acids on inflammation and insulin sensitivity. Current Opinion in Clinical Nutrition and Metabolic Care 14(4): 322-327.
19. Prentki, M.; K. Tornheim, and B.E. Corkey. 1997. Signal transduction mechanisms in nutrient-induced insulin secretion. Diabetologia 40: S32-S41.
20. Rosenstock, J.; N. Aggarwal, D. Polidori, Y. Zhao, D. Arbit, K. Usiskin, G. Capuano, and W. Canovatchel. 2012. Canagliflozin DIA 2001 Study Group, dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabete. Diabetes Care 35: 1232-1238.
21. Stein, D.T.; V. Esser, B.E. Stevenson, K.E. Lane, J.H. Whiteside, M.B. Daniels, S. Chen, and J.D. McGarry. 1996. Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat. The Journal of Clinical Investigation 97: 2728-2735.
22. Stenlöf, K.; W.T. Cefalu, K.A. Kim, M. Alba, K. Usiskin, C. Tong, W. Canovatchel, and G. Meininger. 2013. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes, Obesity & Metabolism 15: 372-382.
23. Stratton, I.M.; A.I. Adler, H.A. Neil, D.R. Matthews, S.E. Manley, C.A. Cull, D. Hadden, R.C. Turner, R.R. Holman, and Diabetes Study Group. 2000. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. British Medical Journal 321: 405-412.
24. Swaminath, G. 2008. Fatty acid binding receptors and their physiological role in type 2 diabetes. Archiv der Pharmazie (Weinheim) 341: 753-761.
25. Tan, C.P.; Y. Feng, Y.P. Zhou, G.J. Eiermann, A. Petrov, C. Zhou, S. Lin, G. Salituro, P. Meinke, R. Mosley, T.E. Akiyama, M. Einstein, S. Kumar, J.P. Berger, S.G. Mills, N.A. Thornberry, L. Yang, and A.D. Howard. 2008. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes 57: 2211-2219.
26. Tsujihata, Y.; R. Ito, M. Suzuki, A. Harada, N. Negoro, T. Yasuma, Y. Momose, and K. Takeuchi. 2011. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. Journal of Pharmacology and Experimental Therapeutics 339: 228-237.
27. Vangaveti, V.; V. Shashidhar, G. Jarrod, B.T. Baune, and R.L. Kennedy. 2010. Free fatty acid receptors: emerging targets for treatment of diabetes and its complications. Therapeutic Advances in Endocrinology and Metabolism 1: 165-175.
28. Zhang, Y.; Jie Hong, Jie Chi, W. Gu, Guang Ning, and W. Wang. 2013. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulphonylureas - A meta-analysis from randomized clinical trials. Diabetes Metab Res Rev. doi: 10.1002/dmrr.2482.